Occupational asthma Occupational asthma - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Occupational asthma Last reviewed: February 2019 Last updated: September 2018 Summary Should be suspected in all adult patients with asthma. An occupational history should be taken to identify work-related causes. Details of work exposures should be obtained from material safety data sheets and other material available (...) to the patient from their workplace. Objective evidence of asthma should be obtained from spirometry, a bronchodilator response, and/or a methacholine challenge. Tests should be performed when the patient is symptomatic and/or within days of having exposure to a suspected aetiological agent. If sensitiser-induced occupational asthma is suspected, additional testing of asthma should be done, preferably while the patient is still working. Whenever possible an immunological response to a suspected work

be considered when evaluating a child with suspected asthma, especially in very young children or when high doses of inhaled corticosteroids are required. Definition Asthma is a chronic respiratory disorder characterised by variable airway inflammation, airway obstruction, and airway hyper-responsiveness. These features interact to determine the clinical symptom pattern of the individual. While the majority of asthmatic children have an intermittent symptom phenotype, the minority have persistent symptoms (...) Asthma in children Asthma in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Asthma in children Last reviewed: February 2019 Last updated: July 2018 Summary As paediatric asthma differs from adult asthma, child-specific asthma guidelines should be used and adult and adolescent guidelines should not be extrapolated to younger age groups. The prevalence of childhood asthma appears to have plateaued in many

Acute asthma exacerbation in adults Acute asthma exacerbation in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Acute asthma exacerbation in adults Last reviewed: February 2019 Last updated: June 2018 Summary Presents as an acute or subacute episode of progressive worsening of symptoms, such as shortness of breath, wheezing, cough, and chest tightness. Pulse rate, respiratory rate, subjective assessment (...) , mechanical ventilation. Pneumonia, pneumothorax, pneumomediastinum, and respiratory failure are complications. Definition An asthma exacerbation is an acute or subacute episode of progressive worsening of symptoms of asthma, including shortness of breath, wheezing, cough, and chest tightness. Exacerbations are marked by decreases from baseline in objective measures of pulmonary function, such as peak expiratory flow rate and FEV1. History and exam presence of risk factors cough wheezing shortness

, based on symptoms. Patients may need to monitor their peak expiratory flow daily and should be aware of the warning signs of a severe attack. Some patients may develop progressive, irreversible obstructive lung disease. Definition Asthma is a chronic inflammatory airway disease characterised by intermittent airway obstruction and hyper-reactivity. Many cellular components are involved in the asthmatic pathway, including mast cells, eosinophils, T lymphocytes, macrophages, neutrophils, and epithelial (...) Asthma in adults Asthma in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Asthma in adults Last reviewed: February 2019 Last updated: June 2018 Summary Patients present with recurrent episodes of shortness of breath, chest tightness, wheezing, or coughing. Examination typically demonstrates an expiratory wheeze; however, in severe asthma there is poor air entry and the chest is silent. Treatment is step-wise

Effect of an Intervention to Promote Breastfeeding on Asthma, Lung Function, and Atopic Eczema at Age 16 Years: Follow-up of the PROBIT Randomized Trial Atopic diseases, including asthma and atopic eczema, are the most common chronic conditions of childhood.To investigate whether an intervention to promote prolonged and exclusive breastfeeding protects against asthma, atopic eczema, and low lung function in adolescence.Follow-up of the Promotion of Breastfeeding Intervention Trial (PROBIT (...) outcomes; secondary outcomes were self-reported asthma diagnosis ever, and wheezing and flexural eczema symptoms in the previous year.A total of 13 557 (79.5%) participants were followed up from September 15, 2012 to July 15, 2015. The intervention (7064 [79.7%]) and control (6493 [79.4%]) groups were similar at follow-up (3590 [50.8%] and 3391 [52.2%] male; mean [SD] age, 16.2 [0.6] and 16.1 [0.5] years, respectively). In the intervention group, 0.3% (21 of 7064) had flexural eczema on skin

Fasenra - benralizumab - Asthma, severe eosinophilic benralizumab | CADTH.ca Find the information you need benralizumab benralizumab Last Updated: January 7, 2019 Result type: Reports Project Number: SR0561-000 Product Line: Generic Name: benralizumab Brand Name: Fasenra Manufacturer: AstraZeneca Canada Inc. Indications: Asthma, severe eosinophilic Manufacturer Requested Reimbursement Criteria 1 : For add-on maintenance treatment of adult patients with severe eosinophilic asthma who (...) are inadequately controlled with high-dose inhaled corticosteroids (ICS) and one or more additional asthma controller(s) (e.g., LABA), if one of the following clinical criteria are met: 1. Blood eosinophil count of 300 cells/L AND have experienced two or more clinically significant asthma exacerbations in the past 12 months, or 2. Blood eosinophil count of 150 cells/L and are treated chronically with oral corticosteroids (OCS). Submission Type: New Project Status: Active Biosimilar: No Date Recommendation

Benralizumab (Fasenra) - For add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype Fasenra (benralizumab) 30 mg/mL Injection U.S. Department of Health and Human Services Search FDA Submit search Fasenra (benralizumab) 30 mg/mL Injection Fasenra Company: AstraZeneca Pharmaceuticals LP Application No.: 761070 Approval Date: 11/14/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

• Depending on the FeNO cutoff, the likelihood of having asthma in people ages 5 years and older increases by 2.8 to 7.0 times given a positive FeNO test result. • FeNO is modestly more accurate in diagnosing steroid-naïve asthmatics, children (ages 5-18), and nonsmokers than other patients suspected to have asthma. • FeNO results can predict which patients will respond to inhaled corticosteroid therapy. • Using FeNO to manage long-term control medications including dose titration, weaning, and monitoring (...) asthma in people ages 5 years and older. Test performance is modestly better in steroid-naïve asthmatics, children, and nonsmokers than the general population with suspected asthma. Algorithms that include FeNO measurements can help in monitoring response to anti-inflammatory or long-term control medications, including dose titration, weaning, or treatment adherence. At this time, there is insufficient evidence supporting the measurement of FeNO in children under the age of 5 as a means

Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma Daily use of inhaled corticosteroids is a widely recommended treatment for mild persistent asthma in children. There is concern that, similar to systemic corticosteroids, inhaled corticosteroids may have adverse effects on bone health.To determine whether there is an increased risk of bone fracture associated with inhaled corticosteroid use in children with asthma.In this population-based nested case (...) -control study, we used health administrative databases to identify a cohort of children aged 2 to 18 years with a physician diagnosis of asthma between April 1, 2003, and March 31, 2014, who were eligible for public drug coverage through the Ontario Drug Benefit Program (Ontario, Canada). We matched cases of first fracture after asthma diagnosis to fracture-free controls (ratio of 1 to 4) based on date of birth (within 1 year), sex, and age at asthma diagnosis (within 2 years). We used a 1-year

request granted - Reconsideration requested Applicant's request for reconsideration placed on CDEC agenda December 12, 2018 CDEC Final Recommendation issued to applicant and drug plans December 19, 2018 CDEC Final Recommendation posted December 21, 2018 Final CADTH review report(s) and patient input posted January 17, 2019 Tags asthma, dry powder inhalers, respiratory, respiclick; arbesda; fluticasone propionate; salmeterol; dry powder inhaler; asthmatic; asthmatics Files Follow us: © 2019 Canadian (...) Arbesda RespiClick - fluticasone propionate / salmeterol xinafoate - Asthma fluticasone propionate / salmeterol xinafoate | CADTH.ca Find the information you need fluticasone propionate / salmeterol xinafoate fluticasone propionate / salmeterol xinafoate Last Updated: March 22, 2019 Result type: Reports Project Number: SR0540-000 Product Line: Generic Name: fluticasone propionate / salmeterol xinafoate Brand Name: Arbesda RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma

, 2018 CDEC Final Recommendation posted December 21, 2018 Final CDR review report(s) and patient input posted January 21, 2019 Tags asthma, dry powder inhalers, respiratory, aermony; fluticasone propionate; dry powder inhaler; asthmatic; asthmatics; respiclick Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Aermony RespiClick - fluticasone propionate - Asthma fluticasone propionate | CADTH.ca Find the information you need fluticasone propionate fluticasone propionate Last Updated: December 21, 2018 Result type: Reports Project Number: SR0539-000 Product Line: Generic Name: fluticasone propionate Brand Name: Aermony RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma Submission Type: New Project Status: Complete Biosimilar: No Date Recommendation Issued: December 19, 2018

The global asthma report 2018 Global Asthma Network The Global Asthma Report 2018Copyright © 2018 The Global Asthma Network All rights reserved. No part of this publication may be reproduced without the permission of the authors and publisher. ISBN: 978-0-473-46523-0 (PRINT) | 978-0-473-46524-7 (ELECTRONIC) The mention or photographs of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the Global Asthma Network in preference (...) to others of a similar nature that are not mentioned. The Global Asthma Network does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. Suggested citation: The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network, 2018 Global Asthma Network www.globalasthmanetwork.org Asthma affects 339 million people.* *For explanation see Chapter 3 “How many people have asthma?” 1 1 1

(OR 0.67 [0.51, 0.88]), especially asthma worsening (OR 0.53 [0.36, 0.77]) or bronchitis (OR 0.42 [0.24, 0.74]). Conclusion. On the basis of published clinical trials reslizumab could be considered as an effective and safe therapeutic option for severe, poorly controlled eosinophilic asthma for the time being. Keywords: meta-analysis as topic, eosinophilia, anti-asthmatic agents, reslizumab, treatment outcome Project of the Serbian Ministry of Education, Science and Technological Development, Grant (...) Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis DOISerbia - Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis - Milosavljević, Miloš N.; Janković, Slobodan M.; Pejčić, Ana V.; Milovanović, Jasmina R.; Opančina, Valentina D.; Kostić, Marina J. doi Serbia Vojnosanitetski pregled 2018 Volume 75, Issue 9, Pages: 884-896 ( 2116 KB) Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta

Meta-analysis of Cesarean Section and Bronchial Asthma in Children Meta-analysis of Cesarean Section and Bronchial Asthma in Children The best way to conference proceedings by Meta-analysis of Cesarean Section and Bronchial Asthma in Children Meta-analysis of Cesarean Section and Bronchial Asthma in Children DOI: 10.25236/bemes.2018.034 Author(s) Yang Kang Corresponding Author Yang Kang Abstract Objective: To investigate the relationship between cesarean section and bronchial asthma (asthma (...) ). Methods: The related literatures of cesarean section and asthma in Pubmed, China Knowledge Network, Wanfang Database and Chongqing Weipu Database were searched and RevMan was applied. 0 The software performs heterogeneity testing and effect value merging on documents that meet the inclusion criteria, along with sensitivity analysis and bias assessment. Results: A total of 8 relevant articles were included, including 32 622 in the asthma group and 890 876 in the control group. There was heterogeneity

Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks ©Institute for Clinical and Economic Review, 2018 Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Final Evidence Report December 20, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page i Final Evidence Report – Biologic Therapies for Treatment of Asthma (...) modelers have any conflicts of interest to disclose ©Institute for Clinical and Economic Review, 2018 Page ii Final Evidence Report – Biologic Therapies for Treatment of Asthma DATE OF PUBLICATION: December 20, 2018 Jeff Tice served as the lead author for this report, with assistance from Judith Walsh. Jeff Tice, Judith Walsh, and Patricia Synnott led the systematic review and authorship of the comparative clinical effectiveness section. Varun Kumar was responsible for oversight of the cost

Breaking through Restricting Bottleneck for Better Asthma Control 29340274 2019 01 28 2450-131X 5 4 2017 Dec Journal of translational internal medicine J Transl Int Med Breaking through Restricting Bottleneck for Better Asthma Control. 192-193 10.1515/jtim-2017-0032 Zhu Ding D Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. Zhang Chao C Department (...) Diseases, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. eng Journal Article 2017 12 29 Poland J Transl Int Med 101673826 2224-4018 Conflict of Interest: None declared. 2018 1 18 6 0 2018 1 18 6 0 2018 1 18 6 1 epublish 29340274 10.1515/jtim-2017-0032 jtim-2017-0032 PMC5767707 Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24 19815809 J Asthma. 2016;53(1):94-100 26383773 Respir Med. 2006 Jul;100(7):1139-51 16713224 J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):293-299

Evaluation of anxiety and depression in mothers of children with asthma Asthma is the most common chronic disease in childhood. Parents have an important role in managing asthma in children. Studies have shown a higher degree of depression and anxiety and lower family performance in mothers of asthmatic children in comparison with the control group.The aim of this study was to evaluate the parenting styles and also depression, anxiety and stress parameters in mothers of children (...) with asthma.This case-control study was performed on 45 mothers of 3 to 15 years old asthmatic children in the allergy clinic of Mashhad University of Medical Sciences, Mashhad, Iran, during the years of 2014 to 2016. The control group was 45 mothers of non-asthmatic children who were matched for the age of their children with the case group in the same population. The parenting styles, as well as depression and anxiety of mothers were evaluated using parenting scales, and the depression-anxiety-stress scales

Stormy weather: a retrospective analysis of demand for emergency medical services during epidemic thunderstorm asthma. To describe the demand for emergency medical assistance during the largest outbreak of thunderstorm asthma reported globally, which occurred on 21 November 2016.A time series analysis was conducted of emergency medical service caseload between 1 January 2015 and 31 December 2016. Demand during the thunderstorm asthma event was compared to historical trends for the overall (...) November, compared with a daily average of 52 during the historical period. After adjustment for temporal trends, thunderstorm asthma was associated with a 42% (95% confidence interval 40% to 44%) increase in overall caseload for the emergency medical service and a 432% increase in emergency medical attendances for acute respiratory distress symptoms. Emergency transports to hospital increased by 17% (16% to 19%) and time critical referrals from general practitioners increased by 47% (21% to 80

Breathing training for dysfunctional breathing in asthma: taking a multidimensional approach Various breathing training programmes may be helpful for adults with asthma. The main therapeutic aim for many of these programmes is the correction of dysfunctional breathing. Dysfunctional breathing can be viewed practically as a multidimensional entity with the three key dimensions being biochemical, biomechanical and psychophysiological. The objectives of this review are to explore how each (...) of these dimensions might impact on asthma sufferers, to review how various breathing therapy protocols target these dimensions and to determine if there is evidence suggesting how breathing therapy protocols might be optimised. Databases and reference lists of articles were searched for peer-reviewed English language studies that discussed asthma or dysfunctional breathing and various breathing therapies. Biochemical, biomechanical and psychophysiological aspects of dysfunctional breathing can all potentially

Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Comparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma eComparative Effectiveness Review Number 202 Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00005-I (...) and safety of bronchial thermoplasty (BT), a procedure that uses heat to remove muscle tissue from the airways of adults with moderate to severe asthma. BT is usually given as three treatments 3 weeks apart. Key Messages • BT along with standard medical management, compared to medical management alone, may improve asthma control and quality of life, but evidence is insufficient to determine impact on asthma exacerbations. • BT along with standard medical management, compared to a similar procedure